SNC THERAPEUTICS, INC.

Evanston, IL · Founded 2022 · CIK 0001966964 · Biotech · Private

Rapamycin-loaded polymersomes (nanoparticles) for inducing antigen-specific immune tolerance in Type 1 diabetes

snctherapeutics.com →
Grants
$350K
1 award
Sector median: 1
Raised
$250K
1 Form D · Mar 2023
43 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$249,999
Federal grantDepartment of Health and Human Services · Phase I · Tolerogenic Nanotherapy to Delay Type I Diabetes$350,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2620KarnaTeq, Inc.—$250K
2621ROME Therapeutics——
2622MSM PROTEIN TECHNOLOGIES, INC—$250K
2623SNC THERAPEUTICS, INC.—$250K
2624Dome Therapeutics, LLC—$250K
2625X1 Biotech Inc.—$235K
2626ZYMTRONIX CATALYTIC SYSTEMS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Margarita ChavezDirector
  • Jeffrey HubbellExecutive Officer
  • Evan ScottDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.